Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib

BACKGROUND: Aicardi-Goutières syndrome (AGS) is a rare hereditary early-onset encephalopathy characterized by upregulation of the type I interferon pathway, poorly responsive to conventional immunosuppression. CASE PRESENTATION: We describe a 7-year-old Chinese boy who developed symptoms at the age...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Peng, Siming, Gao, Sihao, Quan, Meiying, Gou, Lijuan, Wang, Changyan, Sun, Zhixing, Li, Zhuo, Lian, Dongmei, Song, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571391/
https://www.ncbi.nlm.nih.gov/pubmed/37828538
http://dx.doi.org/10.1186/s12969-023-00899-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571391/
https://www.ncbi.nlm.nih.gov/pubmed/37828538
http://dx.doi.org/10.1186/s12969-023-00899-4

Ejemplares similares